Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.

Scientific reports - 24 May 2022

Yao Shuyang, Meric-Bernstam Funda, Hong David, Janku Filip, Naing Aung, Piha-Paul Sarina Anne, Tsimberidou Apostolia Maria, Karp Daniel, Subbiah Vivek, Yap Timothy Anthony, Ahnert Jordi Rodon, Pant Shubham, Dumbrava Ecaterina E Ileana, Wathoo Chetna, Campbell Erick, Yu Lihou, Yamamura Yuko, Fu Siqing

Abstract excerpt

Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic development. We reviewed the medical records of patients with advanced solid tumors harboring CCNE1 amplification who were seen at the phase I clinic between September 1,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase I as Topic
Share to Cyclin E

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to CCNE1 gene

Share to TP53 gene

Share to Mutation

Share to Neoplasms

Share to Oncogene Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 35610322
DOI: 10.1038/s41598-022-12669-5
PMCID: PMC9130298

Genes

CCNE1
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.PMID 35610322Read ↗

Gene amplification <i>CCNE1</i> is related to poor survival and potential therapeutic target in ovarian cancerSemantic proximity Read ↗

Cyclin alterations in diverse cancers: Outcome and co-amplification network.Semantic proximity Read ↗

Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer.Semantic proximity Read ↗

CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.Semantic proximity Read ↗

Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions.Semantic proximity Read ↗

Pan-cancer analysis identifies the oncogenic role of CCNE1 in human cancers.Semantic proximity Read ↗

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.Semantic proximity Read ↗

Enhanced Expression of Human Cyclin G1 (CCNG1) in Tumors, a Novel Biomarker in Development for Cancer Therapy/Gene TherapySemantic proximity Read ↗

Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients – A study of the OVCAD consortiumSemantic proximity Read ↗

CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer modelsSemantic proximity Read ↗

WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcomaSemantic proximity Read ↗

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.